Document:

Amendment to License and Development Agreement

 Exhibit 10.2 
 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF

 DENOTED WITH “***” 
 AMENDMENT TO 
 LICENSE AND DEVELOPMENT AGREEMENT 
 This AMENDMENT TO LICENSE AND DEVELOPMENT AGREEMENT (the “Amendment”) is entered this January 2, 2008 (the “Amendment Date”), by
BioDelivery Sciences International, Inc., a Delaware corporation with offices at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607 (“Parent”), its wholly-owned subsidiary Arius Pharmaceuticals, Inc., a Delaware
corporation with offices at the same address (“Arius”, and together with Parent, “BDSI”) and Meda AB, a Swedish corporation located at Pipers väg 2 A, SE-170 09, Solna, Sweden (“Meda”), 
 RECITALS 
 WHEREAS, BDSI entered into
a License and Development Agreement, dated September 5, 2007, with Meda (the “License Agreement”) concerning the development, marketing and sale of BDSI’s BEMA fentanyl product in the United States, Canada and Mexico; and

 WHEREAS, BDSI and Meda desire to amend the License Agreement as set forth in this Amendment. 
 NOW THEREFORE, in consideration of the mutual covenants herein, and intending to be legally bound hereby, BDSI and Meda agree as follows: 
 1. Definitions. Any capitalized terms not separately defined in this Amendment shall have the meaning provided in the License Agreement. 
 2. Advance Fee. 
  

	 	a.	Meda shall pay to BDSI, upon execution of this Amendment, US$3,000,000. 

  

	 	b.	If FDA approval of an NDA filed with respect to the Fentanyl Product does not occur prior to or on December 1, 2009, BDSI will pay to Meda US$3,200,000 within thirty
(30) days of such date. 

  

	 	c.	All payments under this Section 2 are to be made in United States dollars by wire-transfer of immediately available funds to an account designated by the required recipient of
such funds. 

 3. Amendments. The License Agreement is hereby amended as follows: 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

	 	a.	Section 1.01 of the License Agreement is hereby amended by adding the following definition: 

 “US Approval Milestone” means (i) US$11,900,000 if FDA approval of an NDA filed with respect to the Fentanyl Product occurs on or before
June 30, 2009, (ii) US$11,800,000 if FDA approval of an NDA filed with respect to the Fentanyl Product occurs after June 30, 2009 and on or before December 1, 2009, or (iii) US$15,000,000 if FDA Approval of an NDA filed with
respect to the Fentanyl Product occurs after December 1, 2009.”. 
  

	 	b.	Section 4.02(a) of the License Agreement is hereby amended to read, in its entirety, as follows: 

 “the US Approval Milestone upon FDA approval of an NDA filed with respect to the Fentanyl Product;”. 
  

	 	c.	Section 5.01(d) of the License Agreement is hereby amended to replace the phrase “total of *** first position details of Fentanyl Product to Target Physicians”
with the phrase “total of *** first position details of Fentanyl Product to Target Physicians (which shall include, for purposes of this sentence, physician assistants and nurse practitioners associated with Target Physicians)”.

 4. Governing Law. This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of New
York, without regard to its conflict of law rules. 
 5. Counterparts. This Amendment may be executed in two or more counterparts, each of which shall
be deemed an original, but all of which together shall constitute one and the same instrument. Signature to this Amendment may be transmitted via facsimile, e-mail or other electronic means and such signature shall be deemed to be originals.

 6. Headings. The captions contained in this Amendment are not a part of this Amendment, but are merely guides or labels to assist in locating and
reading the several Sections hereof. 
 7. Effect. To the extent that the terms of the License Agreement are varied by this Amendment, such variations
shall be deemed to be lawfully made amendments to the License Agreement. Except as it may be modified by this Amendment, the License Agreement shall remain unchanged and in full force and effect. 
 [Signature page to follow.] 

 CONFIDENTIAL TREATMENT REQUESTED 
 WITH RESPECT TO CERTAIN PORTIONS HEREOF 
 DENOTED WITH “***” 
  

 IN WITNESS HEREOF, each party hereto has caused this Amendment to be executed in its name effective
as of the date first written above. 
  

									
	Arius Pharmaceuticals, Inc.	 		 	BioDelivery Sciences International, Inc.
					
	By:	 	 /s/ Mark A. Sirgo
	 		 	By:	 	 /s/ Mark A. Sirgo

	Name:	 	Mark A. Sirgo	 		 	Name:	 	Mark A. Sirgo
	Title:	 	President and CEO	 		 	Title:	 	President and CEO
				
		 		 		 	Meda AB
					
		 		 		 	By:	 	 /s/ Anders Lonner

		 		 		 	Name:	 	Anders Lonner
		 		 		 	Title:	 	CEOConsent Agreement

 Exhibit 10.3 
 CONSENT AGREEMENT 
 This CONSENT AGREEMENT (the “Consent”) is entered this January 2,
2009, by BioDelivery Sciences International, Inc., with offices at 801 Corporate Center Drive, Suite 210, Raleigh, North Carolina 27607, its wholly-owned subsidiary Arius Pharmaceuticals, Inc., with offices at the same address (“Arius”;
with Parent, “BDSI”), and CDC IV, LLC, with offices at 47 Hulfish Street, Suite 310, Princeton, New Jersey 08542 (“CDC”). 
 RECITALS 
 WHEREAS, CDC and BDSI are parties to that certain Clinical Development and License Agreement, dated July 14,
2005, as amended (the “CDLA”), and that certain Royalty Purchase and Amendment Agreement, dated September 5, 2007 (the “RPAA”), 
 WHEREAS, BDSI entered into a License and Development Agreement, dated August 2, 2006, with Meda AB, a Swedish corporation located at Pipers väg 2 A, SE-170 09, Solna, Sweden (“Meda”), concerning
the development, marketing and sale of BDSI’s BEMA fentanyl product in Europe (the “EU License”), and a BEMA Fentanyl Supply Agreement, dated August 2, 2006, with Meda, concerning the manufacture and supply of BDSI’s BEMA
Fentanyl Product for Europe (the “EU Supply Agreement”), 
 WHEREAS, BDSI has entered into a License and Development Agreement,
dated September 5, 2007, with Meda concerning the development, marketing and sale of BDSI’s BEMA fentanyl product in the United States, Mexico and Canada (the “NA License”), 
 WHEREAS, CDC is a third-party beneficiary to each of the (i) BEMA License Agreement, dated as of August 2, 2006, by and between Arius and Arius
Two, Inc. (“Arius Two”), as amended by the First Amendment, dated August 6, 2006 (the “Arius EU License”); and (ii) the BEMA License Agreement, dated as of September 5, 2007, by and between Arius and Arius Two (the
“Arius NA License”), 
 WHEREAS, BDSI, CDC, and Meda are parties to a Sublicensing Consent and Amendment, dated August 2,
2006, enabling BDSI and Meda to enter into the EU License (the “EU Consent”) and a Sublicensing Consent and Amendment, dated September 5, 2007, enabling BDSI and Meda to enter into the NA License (the “NA Consent”), and

 WHEREAS, BDSI and Meda wish to amend the EU License and NA License, respectively, pursuant to the forms of amendment attached hereto as
Exhibit A and Exhibit B, respectively (the “EU Amendment” and “NA Amendment”, respectively; collectively, the “Amendments”), and CDC wishes BDSI and Meda to enter into the Amendments. 
 NOW THEREFORE, in consideration of the mutual covenants herein, and intending to be legally bound hereby, BDSI and CDC agree as follows: 

 1. Consents. 
 a. Pursuant to the CDLA and the EU Consent, and as a third party beneficiary to the Arius EU License and Arius NA License, CDC hereby consents to BDSI and Meda entering into the EU Amendment without, in any case, breach of the CDLA, EU
Consent, or any other documents executed by CDC in conjunction with the EU License, which consents shall include, if necessary, but not be limited to, a consent under Section 4 of the EU Consent. CDC hereby agrees that all references to the EU
License, EU Supply Agreement, and the defined terms thereof contained in the EU Consent and any other documents executed by CDC in conjunction with the EU License and EU Supply Agreement shall hereafter apply to the EU License, EU Supply Agreement,
and their defined terms as amended, in each case, by the EU Amendment. 
 b. Pursuant to the CDLA and NA Consent and as a third party
beneficiary to the Arius EU License and Arius NA License, CDC hereby consents to BDSI and Meda entering into the NA Amendment without, in any case, breach of the CDLA, RPAA, NA Consent, or any other documents executed by CDC in conjunction with the
NA License, which consents shall include, if necessary, but not be limited to a consent under Section 4 of the NA Consent and waiver of all rights of Section 6 of the RPAA with respect to the matters contemplated by the NA Amendment. CDC
hereby agrees that all references to the NA License and the defined terms thereof contained in the NA Consent and any other documents executed by CDC in conjunction with the NA License shall hereafter apply to the NA License and its defined terms as
amended, in each case, by the NA Amendment. 
 2. Governing Law. This Consent shall be governed by, and construed and enforced in accordance with, the
laws of the State of New York, without regard to its conflict of law rules. 
 3. Counterparts. This Consent may be executed in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signature to the Consent may be transmitted via facsimile, e-mail or other electronic means and such signature shall be
deemed to be originals. 
 4. Headings. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to
assist in locating and reading the Sections hereof. 
 5. Effect. To the extent that the terms of the CDLA, RPAA, EU Consent, NA Consent, and other
documents executed by CDC in conjunction with the EU License or NA License are varied by this Consent, such variations shall be deemed to be lawfully made amendments to the CDLA, RPAA, EU Consent, NA Consent, and such other documents. Except as it
may be modified by this Consent, the CDLA, RPAA, EU Consent, NA Consent, and such other documents shall remain unchanged and in full force and effect. 
 [Signature page to follow.] 

 IN WITNESS HEREOF, each party hereto has caused this Agreement to be executed in its name effective as of
the date first written above. 
  

									
	Arius Pharmaceuticals, Inc.	 		 	BioDelivery Sciences International, Inc.
					
	By:	 	 /s/ Mark A. Sirgo
	 		 	By:	 	 /s/ Mark A. Sirgo

	Name:	 	Mark A. Sirgo	 		 	Name:	 	Mark A. Sirgo
	Title:	 	President and CEO	 		 	Title:	 	President and CEO
				
		 		 		 	CDC IV, LLC
					
		 		 		 	By:	 	 /s/ David R. Ramsey

		 		 		 	Name:	 	David R. Ramsey
		 		 		 	Title:	 	Partner
				
		 		 		 	MEDA AB
					
		 		 		 	By:	 	 /s/ Anders Lonner

		 		 		 	Name:	 	Anders Lonner
		 		 		 	Title:	 	CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]